178 related articles for article (PubMed ID: 37545363)
1. An overview of the current debate between using minimally invasive surgery versus laparotomy for interval cytoreductive surgery in epithelial ovarian cancer.
Finch L; Chi DS
J Gynecol Oncol; 2023 Sep; 34(5):e84. PubMed ID: 37545363
[TBL] [Abstract][Full Text] [Related]
2. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
[TBL] [Abstract][Full Text] [Related]
3. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
4. Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer.
Conte C; Marchetti C; Loverro M; Giudice MT; Rosati A; Gallotta V; Scambia G; Fagotti A
Int J Gynecol Cancer; 2023 Feb; 33(2):137-144. PubMed ID: 36639195
[TBL] [Abstract][Full Text] [Related]
5. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
[TBL] [Abstract][Full Text] [Related]
6. Minimally invasive interval cytoreductive surgery for advanced ovarian cancer.
Melamed A; Eisenhauer EL
J Surg Oncol; 2024 Jan; 129(1):126-127. PubMed ID: 38073159
[TBL] [Abstract][Full Text] [Related]
7. Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis.
Cardenas-Goicoechea J; Wang Y; McGorray S; Saleem MD; Carbajal Mamani SL; Pomputius AF; Markham MJ; Castagno JC
J Robot Surg; 2019 Feb; 13(1):23-33. PubMed ID: 29992404
[TBL] [Abstract][Full Text] [Related]
8. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
[TBL] [Abstract][Full Text] [Related]
9. The Role of Minimally Invasive Surgery in the Care of Women with Ovarian Cancer: A Systematic Review and Meta-analysis.
Knisely A; Gamble CR; St Clair CM; Hou JY; Khoury-Collado F; Gockley AA; Wright JD; Melamed A
J Minim Invasive Gynecol; 2021 Mar; 28(3):537-543. PubMed ID: 33202311
[TBL] [Abstract][Full Text] [Related]
10. Laparoscopic management of advanced epithelial ovarian cancer after neoadjuvant chemotherapy: a phase II prospective multicenter non-randomized trial (the CILOVE study).
Pomel C; Akladios C; Lambaudie E; Rouzier R; Ferron G; Lecuru F; Classe JM; Fourchotte V; Paillocher N; Wattiez A; Montoriol PF; Thivat E; Beguinot M; Canis M
Int J Gynecol Cancer; 2021 Dec; 31(12):1572-1578. PubMed ID: 34670829
[TBL] [Abstract][Full Text] [Related]
11. [Epithelial ovarian cancers and minimally invasive cytoreductive surgery after neoadjuvant chemotherapy: A systematic review].
Achen G; Koual M; Bentivegna E; Fournier L; Nguyen Xuan HT; Delanoy N; Bats AS; Azaïs H
Gynecol Obstet Fertil Senol; 2021 Oct; 49(10):736-743. PubMed ID: 33636412
[TBL] [Abstract][Full Text] [Related]
12. Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE).
Nitecki R; Rauh-Hain JA; Melamed A; Scambia G; Pareja R; Coleman RL; Ramirez PT; Fagotti A
Int J Gynecol Cancer; 2020 Sep; 30(9):1450-1454. PubMed ID: 32690591
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
14. Survival and Surgical Approach among Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
Persenaire C; Pyrzak A; Barber EL
J Minim Invasive Gynecol; 2022 Mar; 29(3):375-384. PubMed ID: 34648931
[TBL] [Abstract][Full Text] [Related]
15. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
[TBL] [Abstract][Full Text] [Related]
16. Novel Surgical Strategies in the Treatment of Gynecological Malignancies.
Angeles MA; Martínez-Gómez C; Migliorelli F; Voglimacci M; Figurelli J; Motton S; Tanguy Le Gac Y; Ferron G; Martinez A
Curr Treat Options Oncol; 2018 Nov; 19(12):73. PubMed ID: 30411170
[TBL] [Abstract][Full Text] [Related]
17. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
[TBL] [Abstract][Full Text] [Related]
18. Update on the role of surgery in the management of advanced epithelial ovarian cancer.
Straubhar A; Chi DS; Long Roche K
Clin Adv Hematol Oncol; 2020 Nov; 18(11):723-731. PubMed ID: 33406064
[TBL] [Abstract][Full Text] [Related]
19. Robotic interval debulking surgery for advanced epithelial ovarian cancer: current challenge or future direction? A systematic review.
Psomiadou V; Prodromidou A; Fotiou A; Lekka S; Iavazzo C
J Robot Surg; 2021 Apr; 15(2):155-163. PubMed ID: 33037532
[TBL] [Abstract][Full Text] [Related]
20. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
